Previous studies and animal evidence have suggested a relationship between parental tobacco or alcohol use and the risk of some childhood cancers, including neuroblastoma. A case-control study was conducted to investigate the relationship between parental tobacco smoking, alcohol consumption, and risk of neuroblastoma. Cases were children diagnosed with neuroblastoma over the period 1992–1994 at Children’s Cancer Group and Pediatric Oncology Group institutions throughout the United States and Canada. One matched control was selected using random-digit dialing. Information on parental smoking and drinking history was obtained from 504 case and 504 control parents by telephone interview. Overall, there was no consistent pattern of association with parental smoking and alcohol consumption. For example, both maternal smoking and drinking during the period from 1 month before pregnancy through breastfeeding had adjusted odds ratios (ORs) of 1.1 [95% confidence interval (CI), 0.8–1.4]. There was no association with paternal smoking (OR, 1.2; 95% CI, 0.8–1.6) or paternal drinking 1 month before conception (OR, 1.0; 95% CI, 0.7–1.4). There was no consistent increase in risk by the amount of smoking or drinking during any time period relative to pregnancy. There was no suggestion of an increased risk when only one parent smoked. Smoking or drinking among both parents did not jointly increase the risk of neuroblastoma in their offspring. The child’s age at diagnosis, stage, or MYCN oncogene amplification status did not materially alter the OR estimates. It is concluded that the results from this study do not indicate any evidence for a relationship between neuroblastoma and parental tobacco or alcohol use.

Neuroblastoma is an embryonic tumor of the sympathetic nervous system. It is the third most common neoplasm of children under 15 years of age and the most common tumor in infants (1, 2), but little is known about the etiology of neuroblastoma. This early age at diagnosis suggests that prenatal exposures might play an important role. Previous epidemiological studies have reported that an increased risk of neuroblastoma was associated with maternal use of certain medications during pregnancy, parental occupational exposures, and birth characteristics (3).

Tobacco smoke is of interest as a potential risk factor for childhood cancers because it contains a number of mutagenic and carcinogenic compounds that can cross the placenta (4, 5, 6). Of particular interest are N-nitroso compounds (NNOs), which have been shown to induce nervous system tumors in animals (7, 8). Compounds in tobacco smoke, including N-nitroso compounds, can also induce male germ cell mutations (9). Alcohol and its metabolites have been shown to be teratogenic, mutagenic, and carcinogenic (10, 11, 12). Additionally, there have been case reports of fetal alcohol syndrome and neuroblastoma (13). However, parental smoking and alcohol consumption were not consistently associated with an increased risk in previous epidemiological studies (14, 15). This inconsistency may have resulted from the relatively small study sizes,failure to consider specific time windows of exposure, and limited information on confounding factors. We report the results of a large case-control study that evaluated potential risk factors for neuroblastoma, including parental smoking exposure and alcohol consumption during time periods before conception and pregnancy and after birth.

Cases.

Cases were children under age 19 years, newly diagnosed with neuroblastoma during the study period (1992–1994) at member institutions of two North American collaborative clinical trial groups:the Children’s Cancer Group (CCG) and the Pediatric Oncology Group(POG). All of the neuroblastoma cases were pathologically confirmed. Case eligibility criteria included: physician consent; the availability of the biological mother for interview; the ability on the part of the parents to speak either English or Spanish; and the presence of a telephone in the household. Among the 741 potentially eligible cases, a total of 538 (73% of eligible) case mothers were successfully interviewed. A total of 405 case fathers were independently interviewed, and proxy interviews were conducted with case mothers when fathers were unavailable (n = 67; 12%). Reasons for nonparticipation of mothers included physician refusal(n = 90; 12%), mother’s refusal(n = 57; 8%), not traceable (n = 44;6%), and other reasons (n = 12; 2%).

Controls.

One control was selected for each case using a random-digit dialing method based on the first eight digits of the case’s telephone number (16). Each randomly selected control number was contacted up to 6 times. Controls were individually matched to cases on date of birth (±6 months for cases ≤3 years of age and ±1 year for cases >3 years of age). The response proportion for the random-digit dialing screening phase was 74%. Eligibility criteria for controls were the same as for the cases. Among the 703 eligible controls, 504(72%) control mothers were successfully interviewed, and 304 control fathers were directly interviewed. Proxy interview for fathers was obtained for 142 (28%) controls. The reasons for mothers’nonparticipation were refusal (n = 143; 20%) or not traceable (n = 57; 8%).

Interview.

Trained interviewers administered a structured telephone interview to parents. Parents of cases and controls were asked for information about occupational history, medication use, pregnancy history,pregnancy and birth complications, and other factors. Parental smoking history included smoking status (never, past, and current), timing of smoking (month before the index pregnancy; first, second, and third trimesters separately; after birth; and during breastfeeding),intensity of smoking (number of cigarettes or packs per day), and duration of smoking (years). Ever-smoking was defined as a history of smoking at least one cigarette per day for 6 months or longer. In addition, information on tobacco type (cigarette, cigar, pipe, chewing,snuff) was also requested from fathers. Mothers of cases and controls were asked about alcohol consumption with respect to timing (month before, during pregnancy, and during breastfeeding), types of alcohol(wine, beer, and hard liquor), frequency and quantity of consumption(glass/cans of beer or shots of liquor or glasses of wine per day,week, or month). For paternal alcohol consumption, the timing of exposure was restricted to 2–12 months and 1 month before pregnancy.

Data Analysis.

We estimated the risk of neuroblastoma associated with parental cigarette smoking and alcohol consumption using conditional logistic regression. Cigarette smoking was analyzed as dichotomous (no, yes) and quantitative (cigarettes per day and pack-years) variables. Paternal smoking was also evaluated according to type of tobacco consumed. The total amount of alcohol consumption was calculated by summing the number of grams of alcohol for all of the three types of alcoholic beverages. It was assumed that a 12-ounce bottle or can of beer contained 12.8 g of alcohol; a 4-ounce glass of wine contained 10.8 g of alcohol; and a 1.5-ounce shot of liquor contained 15.1 g of alcohol (United States Department of Agriculture Nutrient Database for Standard Reference, Release 12, March 1998). Alcohol consumption was examined in different forms: a dichotomous variable (none, yes), a quantitative variable (grams per day), and by type (beer, wine, and liquor). The exposure variables were further evaluated based on the timing of exposure such as before pregnancy; in first, second, and third trimesters; during breastfeeding; and after birth. In the analyses of the fathers’ data, results from the entire dataset (direct and proxy interview combined) were compared with the analysis of data from direct paternal interview.

Maternal education, household income in the birth year, child’s gender, and mother’s race were included as potential confounders in the logistic regression analysis. The joint effects (interaction) of maternal and paternal smoking as well as parental drinking were also evaluated. Child’s age at diagnosis was investigated as a potential effect modifier. Because stage and tumor MYCN oncogene amplification status may represent a clinically and genetically distinct subgroup of neuroblastoma cases (17), additional analyses were conducted among the subgroups defined by these factors. The International Neuroblastoma Staging System was used. MYCN copy number was determined by Southern blot (18) or fluorescence in situ hybridization (19).

In total, 504 matched pairs were used for the analysis of maternal smoking and alcohol consumption. Of the 409 cases with staging data, 16% were stage 1, 6% stage 2a, 6% stage 2b, 18% stage 3, 46%stage 4, and 7% stage 4S. A total of 381 cases had MYCNdata, with 67 case tumors having detectable amplification. Complete information about paternal exposure was available for 390 matched pairs. Table 1 presents the distribution of cases and controls according to selected sociodemographic factors. Slight case-control differences were found for gender and maternal race. More case mothers than control mothers had less than a high school education(OR,3 2.2; 95% CI, 0.8–6.3). There was also some indication of cases being more likely than controls to have lived in a household with an income either <$10,000 or >$50,000 in the year of the birth. There was some indication of an increased risk of advanced maternal age (≥40 years), although the estimate was imprecise. The pattern of case-control difference was similar for paternal demographic characteristics (data not shown).

Overall, 40% of women in the case group and 38% of women in the control group had ever smoked (OR, 1.0; CI, 0.7–1.3). No association with smoking around pregnancy (1 month before pregnancy through breastfeeding; OR, 1.1; CI, 0.8–1.4) was found (Table 2). Smoking before pregnancy, during pregnancy (three trimesters), or during breastfeeding did not show any increased risk. Further evaluation of the average number of cigarettes smoked per day during the first and second trimesters did not show any pattern of association, although the estimates were imprecise. Similar results were found for the amount of smoking during other time periods and the duration of smoking during pregnancy (data not shown).

Overall, there was no association observed for women who ever drank alcohol around pregnancy (OR, 1.1; CI, 0.8–1.4; Table 3). There were moderate associations with drinking during the first,second, and third trimesters, with the strongest effect in the second trimester (OR = 1.6; CI = 1.0–2.4). However, when the amount of alcohol consumption during those specific periods was evaluated, a strong dose-response gradient was not found, although the category 1.5–5 g/day showed elevated but imprecise ORs in the first (OR, 1.9;CI, 0.9–3.9) and second (OR, 2.1; CI, 0.8–5.3) trimesters. No association was found with the type of alcohol (wine, beer, or liquor)that women consumed.

With respect to paternal smoking, 46.4% of case fathers and 45.5% of control fathers ever smoked, on average, at least one cigarette per day for at least 6 months during their lifetime (OR, 1.0;CI, 0.7–1.3; Table 4). No elevated ORs were observed for smoking around pregnancy (OR, 1.0;CI, 0.7–1.4) and during each trimester (Table 4). Dose-response relationships were not found for average number cigarette per day,pack-years, or duration of smoking. However, a weak association was found for smoking more than 20 cigarettes per day during the month before pregnancy (OR, 1.5; CI, 0.8–2.7). There was no association with smokeless tobacco use. Cigar and pipe smoking could not be evaluated because of the small number of users. Additional analyses of paternal smoking among offspring of nonsmoking mothers did not reveal any important elevations in risk. No differences were found using only paternal self-reported data.

No associations were found for lifetime paternal drinking (OR, 0.8; CI,0.5–1.1), drinking 2–12 months before pregnancy (OR, 1.1; CI,0.8–1.6), or one month before pregnancy (OR, 1.0; CI, 0.7–1.4; Table 5). There was no suggestion of a dose-response relationship for amount of alcohol consumption per day or variation in risk according to type of alcohol consumed. Analysis of smoking and alcohol consumption history using only the direct self-reported information gave similar results(data not shown). No substantial changes were shown from the analysis controlling for maternal smoking and drinking status.

The joint effects of maternal smoking and paternal smoking as well as maternal drinking and paternal drinking were also examined (data not shown). Using nonsmokers (or nondrinkers) as the reference category, we found no increased risk for any separate or joint effect. For example,with a history of both parents having smoked around pregnancy the OR was 1.3 (CI, 0.9–2.0) and for both parents having reported drinking around pregnancy the OR was 1.2 (CI, 0.8–1.8). The results did not differ for other time periods or using only paternal self-report data.

The evaluation of parental smoking and alcohol consumption did not show heterogeneity based on age at diagnosis (data not shown). We also analyzed case subgroups based on case MYCNamplification status or stage and did not find a consistent pattern of association. For example, maternal smoking around pregnancy was associated with an imprecise risk estimate among cases with a tumor that had MYNC amplification (maternal smoking and MYCN+ OR,0.7; CI, 0.3–1.9; maternal smoking and MYCN– OR, 1.0; CI,0.7–1.5).

Our study was the first to comprehensively evaluate the effect of parental smoking and alcohol consumption on the risk of neuroblastoma,including the evaluation of timing of exposure, type of tobacco and alcohol used, and joint effects of both parents’ smoking and alcohol consumption. Overall, we did not find any consistent pattern of association with parental smoking or alcohol consumption during specific periods before, during, or after pregnancy.

Two studies have investigated parental smoking and alcohol consumption as potential risk factors for neuroblastoma, but the results were inconsistent. A study of 104 neuroblastoma cases identified by the Greater Delaware Valley Registry (14)reported an elevated OR for maternal alcohol consumption of one or more drinks per day during pregnancy (OR, 9.0; CI, 2.16–37.56) and for maternal binge alcohol consumption of three or more drinks per day during pregnancy (OR, 6.0; CI, 1.26–28.54). No association with maternal cigarette smoking before or during pregnancy was found (OR,1.3; CI, 0.8–2.1). Another study (15) based on 101 cases and children with other cancers as controls found an elevated risk with maternal smoking during the year before the child’s birth (OR, 1.9;CI, 1.1–3.2), but it did not find an association with maternal alcohol consumption (OR, 0.7; CI, 0.4–1.1). Random error, the time period when the studies were conducted, and variation in control groups may explain some of the differences among study findings. The relatively small sample size is the major limitation of those studies. In addition, they did not obtain detailed information on the amount of tobacco and alcohol used during different time periods before, during, and after pregnancy. Our relatively large study size allowed us to evaluate changes in consumption levels before and during pregnancy.

The response proportions in both case and control groups were below 75%, which may indicate potential selection bias. We do not have direct information to characterize nonresponders. However, the age at diagnosis in our case group is similar to the distribution in Surveillance, Epidemiology, and End Results data (1).

Misclassification of parental smoking and drinking behaviors is also a concern. Studies with cotinine measurements have shown that pregnant women accurately report whether they had smoked (20, 21);however, they do not accurately report the actual number of cigarettes smoked. In general, good agreement between self-reported alcohol consumption and detailed records for both women and men has been found (22). Onestudy examined potential misclassification of alcohol and cigarette use during pregnancy in relation to several adverse outcomes, including congenital malformations, and reported little differential reporting bias (23).

In our case group, we had fewer fathers with proxy data (12%)compared with control fathers (28%). To evaluate the effect of this potential problem, we repeated the analyses using only paternal self-reported information and no substantial differences were observed. Although we examined the risk of paternal smoking among children of nonsmoking mothers and the risk of maternal smoking with nonsmoking fathers, we did not directly measure passive smoking exposure from relatives or others in the household. In conclusion, the results of our large comprehensive study indicate that parental smoking or alcohol consumption does not increase the risk of neuroblastoma.

Appendices

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

        
1

This study was supported in part by Grant CA57004 from the National Cancer Institute and by numerous grants from the Division of Cancer Treatment, National Cancer Institute, NIH Department of Health and Human Services to Children’s Cancer Group and Pediatric Oncology Group investigators, listed with their institutions and grant numbers in the .

                
3

The abbreviations used are: OR, odds ratio; CI,confidence interval.

Table 1

Demographic factors

FactorCaseControlORa95% CI
n%n%
Gender       
Male 279 55.4 251 49.8 1.0  
Female 225 44.6 253 50.2 0.8 0.6–1.0 
Mother’s race       
White 409 81.2 396 78.6 1.0  
Black 36 7.1 39 7.7 0.7 0.4–1.4 
Hispanic 41 8.1 54 10.7 0.6 0.4–1.1 
Other 18 3.6 15 3.0 1.3 0.6–2.8 
Mother’s education       
<High school 54 10.7 51 10.1 2.2 0.8–6.3 
High school 341 67.7 318 63.1 1.3 0.9–1.8 
College 109 21.6 135 26.8 1.0  
Mother’s age       
<20 yr 44 8.7 35 6.9 1.3 0.6–2.7 
20–24 112 22.2 110 21.8 1.2 0.8–1.8 
25–30 200 39.7 206 40.9 1.0  
31–39 138 27.4 146 29.0 0.8 0.6–1.2 
40+ 10 2.0 1.4 3.5 0.7–16.8 
Household income in birth year (in thousands)       
<$10 84 17.7 54 11.1 1.6 0.8–3.3 
$10–20 85 17.9 91 18.7 1.4 0.7–2.7 
$21–30 82 17.3 114 23.5 1.0  
$31–40 73 15.4 86 17.7 1.8 0.9–3.6 
$41–50 51 10.7 52 10.7 1.0 0.4–2.3 
>$50 100 21.0 89 18.3 1.6 0.7–3.5 
FactorCaseControlORa95% CI
n%n%
Gender       
Male 279 55.4 251 49.8 1.0  
Female 225 44.6 253 50.2 0.8 0.6–1.0 
Mother’s race       
White 409 81.2 396 78.6 1.0  
Black 36 7.1 39 7.7 0.7 0.4–1.4 
Hispanic 41 8.1 54 10.7 0.6 0.4–1.1 
Other 18 3.6 15 3.0 1.3 0.6–2.8 
Mother’s education       
<High school 54 10.7 51 10.1 2.2 0.8–6.3 
High school 341 67.7 318 63.1 1.3 0.9–1.8 
College 109 21.6 135 26.8 1.0  
Mother’s age       
<20 yr 44 8.7 35 6.9 1.3 0.6–2.7 
20–24 112 22.2 110 21.8 1.2 0.8–1.8 
25–30 200 39.7 206 40.9 1.0  
31–39 138 27.4 146 29.0 0.8 0.6–1.2 
40+ 10 2.0 1.4 3.5 0.7–16.8 
Household income in birth year (in thousands)       
<$10 84 17.7 54 11.1 1.6 0.8–3.3 
$10–20 85 17.9 91 18.7 1.4 0.7–2.7 
$21–30 82 17.3 114 23.5 1.0  
$31–40 73 15.4 86 17.7 1.8 0.9–3.6 
$41–50 51 10.7 52 10.7 1.0 0.4–2.3 
>$50 100 21.0 89 18.3 1.6 0.7–3.5 
a

Unadjusted matched OR.

Table 2

Maternal smoking

Maternal smokingaCaseControlORb95% CI
n%n%
Lifetime       
Never 299 59.7 311 61.8 1.0  
Ever 202 40.3 192 38.2 1.0 0.7–1.3 
Around pregnancyc       
Never 351 70.1 371 73.8 1.0  
Ever 150 29.9 132 26.2 1.1 0.8–1.4 
1 mo before conception       
Never 354 70.7 371 73.8 1.0  
Ever 147 29.3 132 26.2 1.1 0.8–1.4 
1st trimester       
Never 390 77.8 401 79.7 1.0  
Ever 111 22.2 102 20.3 1.0 0.7–1.3 
2nd trimester       
Never 414 82.6 421 83.7 1.0  
Ever 87 17.4 82 16.3 0.9 0.7–1.3 
3rd trimester       
Never 410 81.2 421 83.7 1.0  
Ever 91 18.2 82 16.3 1.0 0.7–1.4 
Breastfeeding       
Never 364 92.2 377 90.8 1.0  
Ever 31 7.9 38 9.2 0.9 0.5–1.5 
Cigarettes/day during 1st trimester       
Nonsmoker 390 78.0 401 79.9 1.0  
≤5 22 4.4 25 5.0 0.8 0.5–1.5 
5–10 39 7.8 34 6.8 1.0 0.6–1.6 
10–15 12 2.4 1.8 1.2 0.5–3.0 
>15 37 7.4 33 6.6 0.9 0.6–1.6 
Cigarettes/day during 2nd trimester       
Nonsmoker 414 82.8 421 84.0 1.0  
≤5 17 3.4 16 3.2 1.0 0.5–2.0 
5–10 34 6.8 30 6.0 1.0 0.6–1.6 
10–15 11 2.2 1.4 1.3 0.5–3.5 
>15 24 4.8 27 5.4 0.8 0.4–1.4 
Maternal smokingaCaseControlORb95% CI
n%n%
Lifetime       
Never 299 59.7 311 61.8 1.0  
Ever 202 40.3 192 38.2 1.0 0.7–1.3 
Around pregnancyc       
Never 351 70.1 371 73.8 1.0  
Ever 150 29.9 132 26.2 1.1 0.8–1.4 
1 mo before conception       
Never 354 70.7 371 73.8 1.0  
Ever 147 29.3 132 26.2 1.1 0.8–1.4 
1st trimester       
Never 390 77.8 401 79.7 1.0  
Ever 111 22.2 102 20.3 1.0 0.7–1.3 
2nd trimester       
Never 414 82.6 421 83.7 1.0  
Ever 87 17.4 82 16.3 0.9 0.7–1.3 
3rd trimester       
Never 410 81.2 421 83.7 1.0  
Ever 91 18.2 82 16.3 1.0 0.7–1.4 
Breastfeeding       
Never 364 92.2 377 90.8 1.0  
Ever 31 7.9 38 9.2 0.9 0.5–1.5 
Cigarettes/day during 1st trimester       
Nonsmoker 390 78.0 401 79.9 1.0  
≤5 22 4.4 25 5.0 0.8 0.5–1.5 
5–10 39 7.8 34 6.8 1.0 0.6–1.6 
10–15 12 2.4 1.8 1.2 0.5–3.0 
>15 37 7.4 33 6.6 0.9 0.6–1.6 
Cigarettes/day during 2nd trimester       
Nonsmoker 414 82.8 421 84.0 1.0  
≤5 17 3.4 16 3.2 1.0 0.5–2.0 
5–10 34 6.8 30 6.0 1.0 0.6–1.6 
10–15 11 2.2 1.4 1.3 0.5–3.5 
>15 24 4.8 27 5.4 0.8 0.4–1.4 
a

A total of three cases and one control had missing smoking-history information.

b

Adjusted for child’s gender,mother’s race and education, and household income in the birth year.

c

Included 1 month before and during the pregnancy and during breastfeeding.

Table 3

Maternal alcohol consumption

Maternal drinkingaCaseControlORb95% CI
n%n%
Lifetime       
Never 247 49.4 244 48.5 1.0  
Ever 253 50.6 259 51.5 0.9 0.7–1.1 
Around pregnancyc       
Never 264 52.9 281 56.1 1.0  
Ever 235 47.1 220 43.9 1.1 0.8–1.4 
1 mo before conception       
Never 294 58.9 312 62.3 1.0  
Ever 205 41.1 189 37.7 1.1 0.8–1.4 
1st trimester       
Never 403 80.8 423 84.4 1.0  
Ever 96 19.2 78 15.6 1.2 0.9–1.7 
2nd trimester       
Never 439 88.0 461 92.0 1.0  
Ever 60 12.0 40 8.0 1.6 1.0–2.4 
3rd trimester       
Never 441 88.4 458 91.4 1.0  
Ever 58 11.6 43 8.6 1.4 0.9–2.1 
Breastfeeding       
Never 266 83.1 284 85.5 1.0  
Ever 54 16.9 48 14.5 1.0 0.5–2.0 
1st trimester (g/day)       
Nondrinker 429 86.0 450 89.8 1.0  
≤1.5 26 5.2 22 4.4 1.1 0.6–1.9 
1.5–5 24 4.8 13 2.6 1.9 0.9–3.9 
>5 20 4.0 16 3.2 1.0 0.5–2.1 
2nd trimester (g/day)       
Nondrinker 458 91.8 471 94.0 1.0  
≤1.5 23 4.6 19 3.8 1.2 0.6–2.2 
1.5–5 15 3.0 1.4 2.1 0.8–5.3 
>5 0.6 0.8 0.9 0.2–4.0 
Maternal drinkingaCaseControlORb95% CI
n%n%
Lifetime       
Never 247 49.4 244 48.5 1.0  
Ever 253 50.6 259 51.5 0.9 0.7–1.1 
Around pregnancyc       
Never 264 52.9 281 56.1 1.0  
Ever 235 47.1 220 43.9 1.1 0.8–1.4 
1 mo before conception       
Never 294 58.9 312 62.3 1.0  
Ever 205 41.1 189 37.7 1.1 0.8–1.4 
1st trimester       
Never 403 80.8 423 84.4 1.0  
Ever 96 19.2 78 15.6 1.2 0.9–1.7 
2nd trimester       
Never 439 88.0 461 92.0 1.0  
Ever 60 12.0 40 8.0 1.6 1.0–2.4 
3rd trimester       
Never 441 88.4 458 91.4 1.0  
Ever 58 11.6 43 8.6 1.4 0.9–2.1 
Breastfeeding       
Never 266 83.1 284 85.5 1.0  
Ever 54 16.9 48 14.5 1.0 0.5–2.0 
1st trimester (g/day)       
Nondrinker 429 86.0 450 89.8 1.0  
≤1.5 26 5.2 22 4.4 1.1 0.6–1.9 
1.5–5 24 4.8 13 2.6 1.9 0.9–3.9 
>5 20 4.0 16 3.2 1.0 0.5–2.1 
2nd trimester (g/day)       
Nondrinker 458 91.8 471 94.0 1.0  
≤1.5 23 4.6 19 3.8 1.2 0.6–2.2 
1.5–5 15 3.0 1.4 2.1 0.8–5.3 
>5 0.6 0.8 0.9 0.2–4.0 
a

A total of four cases and one control had missing information on alcohol use history.

b

Adjusted for child’s gender,mother’s race and education, and household income in the birth year.

c

Included 1 month before and during the pregnancy and during breastfeeding.

Table 4

Paternal smoking

Paternal smokingaCaseControlORb95% CI
n%n%
Lifetime       
Never 209 53.6 212 54.5 1.0  
Ever 181 46.4 177 45.5 1.0 0.7–1.3 
Around pregnancyc       
Never 248 63.6 253 65.5 1.0  
Ever 142 36.4 133 34.5 1.0 0.7–1.4 
1 mo before conception       
Never 253 64.9 267 68.6 1.0  
Ever 137 35.1 122 31.4 1.2 0.8–1.6 
1st trimester       
Never 260 66.7 269 69.2 1.0  
Ever 130 33.3 120 30.9 1.1 0.8–1.5 
Cigsd/day 1 mo before conception       
253 65.5 267 69.2 1.0  
≤5 15 3.9 13 3.4 1.3 0.6–2.8 
5–10 24 6.2 24 6.2 1.0 0.5–1.9 
10–20 60 15.5 58 15.0 1.1 0.7–1.7 
>20 34 8.8 24 6.2 1.5 0.8–2.7 
Cigs/day during 1st trimester       
260 67.4 269 70.1   
≤5 14 3.6 12 3.1 1.3 0.5–3.0 
5–10 20 5.2 22 5.7 0.9 0.5–1.8 
10–20 61 15.8 57 14.8 1.1 0.7–1.7 
>20 31 8.0 24 6.3 1.3 0.7–2.3 
Smokeless tobacco 1 mo before conception       
Never 348 93.1 365 94.1   
Ever 26 7.0 23 5.9 1.3 0.7–2.6 
Paternal smokingaCaseControlORb95% CI
n%n%
Lifetime       
Never 209 53.6 212 54.5 1.0  
Ever 181 46.4 177 45.5 1.0 0.7–1.3 
Around pregnancyc       
Never 248 63.6 253 65.5 1.0  
Ever 142 36.4 133 34.5 1.0 0.7–1.4 
1 mo before conception       
Never 253 64.9 267 68.6 1.0  
Ever 137 35.1 122 31.4 1.2 0.8–1.6 
1st trimester       
Never 260 66.7 269 69.2 1.0  
Ever 130 33.3 120 30.9 1.1 0.8–1.5 
Cigsd/day 1 mo before conception       
253 65.5 267 69.2 1.0  
≤5 15 3.9 13 3.4 1.3 0.6–2.8 
5–10 24 6.2 24 6.2 1.0 0.5–1.9 
10–20 60 15.5 58 15.0 1.1 0.7–1.7 
>20 34 8.8 24 6.2 1.5 0.8–2.7 
Cigs/day during 1st trimester       
260 67.4 269 70.1   
≤5 14 3.6 12 3.1 1.3 0.5–3.0 
5–10 20 5.2 22 5.7 0.9 0.5–1.8 
10–20 61 15.8 57 14.8 1.1 0.7–1.7 
>20 31 8.0 24 6.3 1.3 0.7–2.3 
Smokeless tobacco 1 mo before conception       
Never 348 93.1 365 94.1   
Ever 26 7.0 23 5.9 1.3 0.7–2.6 
a

A total of one control had missing information on tobacco use history. Includes direct and proxy data.

b

Adjusted for child’s gender,mother’s race, father’s education, and household income in birth year.

c

Included 1 month before and during the pregnancy.

d

Cigs, cigarettes.

Table 5

Paternal alcohol consumption

Paternal drinkingaCaseControlORb95% CI
n%n%
Lifetime       
Never 94 24.4 81 20.9 1.0  
Ever 291 75.6 307 79.1 0.8 0.5–1.1 
During 1 y before pregnancy       
Never 77 19.9 81 21.0 1.0  
Ever 310 80.1 305 79.0 1.2 0.8–1.7 
2–12 mo before pregnancy       
Never 79 20.4 81 21.0 1.0  
Ever 308 79.6 305 79.0 1.1 0.8–1.6 
1 mo before pregnancy       
Never 118 30.5 115 29.8 1.0  
Ever 269 69.5 271 70.2 1.0 0.7–1.4 
1 mo before pregnancy (g/day)       
122 31.6 117 31.0 1.0  
≤1.5 25 6.5 22 5.8 1.2 0.6–2.2 
1.5–5 46 11.9 56 14.8 0.9 0.5–1.4 
5–15 88 22.8 97 25.7 0.9 0.6–1.4 
15–25 34 8.8 26 6.9 1.4 0.8–2.6 
>25 71 18.4 60 15.9 1.3 0.8–2.1 
Paternal drinkingaCaseControlORb95% CI
n%n%
Lifetime       
Never 94 24.4 81 20.9 1.0  
Ever 291 75.6 307 79.1 0.8 0.5–1.1 
During 1 y before pregnancy       
Never 77 19.9 81 21.0 1.0  
Ever 310 80.1 305 79.0 1.2 0.8–1.7 
2–12 mo before pregnancy       
Never 79 20.4 81 21.0 1.0  
Ever 308 79.6 305 79.0 1.1 0.8–1.6 
1 mo before pregnancy       
Never 118 30.5 115 29.8 1.0  
Ever 269 69.5 271 70.2 1.0 0.7–1.4 
1 mo before pregnancy (g/day)       
122 31.6 117 31.0 1.0  
≤1.5 25 6.5 22 5.8 1.2 0.6–2.2 
1.5–5 46 11.9 56 14.8 0.9 0.5–1.4 
5–15 88 22.8 97 25.7 0.9 0.6–1.4 
15–25 34 8.8 26 6.9 1.4 0.8–2.6 
>25 71 18.4 60 15.9 1.3 0.8–2.1 
a

A total of four cases and two controls had missing information on alcohol use history. Includes direct and proxy data.

b

Adjusted for child’s gender,mother’s race, father’s education, and household income in birth year.

Appendix A

Participating principal investigators—Children’s Cancer Group

Institution Investigators Grant no. 
Group Operations Center, Arcadia, CA W. Archie Bleyer, Anita Khayat, Harland Sather, Mark Krailo, Jonathan Buckley, Daniel Stram, and Richard Sposto CA 13539 
University of Michigan Medical Center, Ann Arbor, MI Raymond Hutchinson CA 02971 
University of California Medical Center, San Francisco, CA Katherine Matthay CA 17829 
University of Wisconsin Hospital, Madison, WI Diane Puccetti CA 05436 
Children’s Hospital & Medical Center, Seattle, WA J. Russell Geyer CA 10382 
Rainbow Babies & Children’s Hospital, Cleveland, OH Eric Kodish CA 20320 
Children’s National Medical Center, Washington, D.C. Gregory Reaman CA 03888 
Children’s Hospital of Los Angeles, Los Angeles, CA Paul Gaynon CA 02649 
Children’s Hospital of Columbus, Columbus, OH Frederick Ruymann CA 03750 
Columbia Presbyterian College of Physicians & Surgeons, New York, NY Michael Weiner CA 03526 
Children’s Hospital of Pittsburgh, Pittsburgh, PA A. Kim Ritchey CA 36015 
Vanderbilt University School of Medicine, Nashville, TN James Whitlock CA 26270 
Doernbecher Memorial Hospital for Children, Portland, OR H. Stacy Nicholson CA 26044 
University of Minnesota Health Sciences Center, Minneapolis, MN Joseph Neglia CA 07306 
Children’s Hospital of Philadelphia, Philadelphia, PA Beverly Lange CA 11796 
Memorial Sloan-Kettering Cancer Center, New York, NY Peter Steinherz CA 42764 
James Whitcomb Riley Hospital for Children, Indianapolis, IN Philip Breitfeld CA 13809 
University of Utah Medical Center, Salt Lake City, UT William Carroll CA 10198 
University of British Columbia, Vancouver, British Columbia, Canada Paul Rogers CA 29013 
Children’s Hospital Medical Center, Cincinnati, OH Robert Wells CA 26126 
Harbor University of California-Los Angeles & Miller Children’s Medical Center, Torrance/Long Beach, CA Jerry Finklestein CA 14560 
University of California Medical Center (University of California-Los Angeles), Los Angeles, CA Stephen Feig CA 27678 
University of Iowa Hospitals and Clinics, Iowa City, IA Raymond Tannous CA 29314 
Childrens Hospital of Denver, Denver, CO Lorrie Odom CA 28851 
Mayo Clinic and Foundation, Rochester, MN Gerald Gilchrist CA 28882 
University of North Carolina, Chapel Hill, NC Stuart Gold  
University of Medicine & Dentistry of New Jersey, Camden, NJ Richard Drachtman  
Children’s Mercy Hospital, Kansas City, MO Maxine Hetherington  
Wyler Children’s Hospital, Chicago, IL James Nachman  
M. D. Anderson Cancer Center, Houston, TX Beverly Raney  
New York University Medical Center, New York, NY Aaron Rausen  
Childrens Hospital of Orange County, Orange, CA Violet Shen  
Institution Investigators Grant no. 
Group Operations Center, Arcadia, CA W. Archie Bleyer, Anita Khayat, Harland Sather, Mark Krailo, Jonathan Buckley, Daniel Stram, and Richard Sposto CA 13539 
University of Michigan Medical Center, Ann Arbor, MI Raymond Hutchinson CA 02971 
University of California Medical Center, San Francisco, CA Katherine Matthay CA 17829 
University of Wisconsin Hospital, Madison, WI Diane Puccetti CA 05436 
Children’s Hospital & Medical Center, Seattle, WA J. Russell Geyer CA 10382 
Rainbow Babies & Children’s Hospital, Cleveland, OH Eric Kodish CA 20320 
Children’s National Medical Center, Washington, D.C. Gregory Reaman CA 03888 
Children’s Hospital of Los Angeles, Los Angeles, CA Paul Gaynon CA 02649 
Children’s Hospital of Columbus, Columbus, OH Frederick Ruymann CA 03750 
Columbia Presbyterian College of Physicians & Surgeons, New York, NY Michael Weiner CA 03526 
Children’s Hospital of Pittsburgh, Pittsburgh, PA A. Kim Ritchey CA 36015 
Vanderbilt University School of Medicine, Nashville, TN James Whitlock CA 26270 
Doernbecher Memorial Hospital for Children, Portland, OR H. Stacy Nicholson CA 26044 
University of Minnesota Health Sciences Center, Minneapolis, MN Joseph Neglia CA 07306 
Children’s Hospital of Philadelphia, Philadelphia, PA Beverly Lange CA 11796 
Memorial Sloan-Kettering Cancer Center, New York, NY Peter Steinherz CA 42764 
James Whitcomb Riley Hospital for Children, Indianapolis, IN Philip Breitfeld CA 13809 
University of Utah Medical Center, Salt Lake City, UT William Carroll CA 10198 
University of British Columbia, Vancouver, British Columbia, Canada Paul Rogers CA 29013 
Children’s Hospital Medical Center, Cincinnati, OH Robert Wells CA 26126 
Harbor University of California-Los Angeles & Miller Children’s Medical Center, Torrance/Long Beach, CA Jerry Finklestein CA 14560 
University of California Medical Center (University of California-Los Angeles), Los Angeles, CA Stephen Feig CA 27678 
University of Iowa Hospitals and Clinics, Iowa City, IA Raymond Tannous CA 29314 
Childrens Hospital of Denver, Denver, CO Lorrie Odom CA 28851 
Mayo Clinic and Foundation, Rochester, MN Gerald Gilchrist CA 28882 
University of North Carolina, Chapel Hill, NC Stuart Gold  
University of Medicine & Dentistry of New Jersey, Camden, NJ Richard Drachtman  
Children’s Mercy Hospital, Kansas City, MO Maxine Hetherington  
Wyler Children’s Hospital, Chicago, IL James Nachman  
M. D. Anderson Cancer Center, Houston, TX Beverly Raney  
New York University Medical Center, New York, NY Aaron Rausen  
Childrens Hospital of Orange County, Orange, CA Violet Shen  

Appendix B

Participating principal investigators—Pediatric Oncology Group

InstitutionPrincipal investigatorGrant no.
Baylor C. Philip Steuber CA 03161 
Hackensack Medical Center Michael B. Harris  
Boston Floating Hospital Cynthia Sweetnam Kretschmar  
East Carolina University Charles W. Daeschner CA 69177 
Medical University of South Carolina Joseph Laver CA 69177 
Children’s Hospital Michigan Yaddanapudi Ravindranath CA 29691 
St. Johns Hospital Hadi Sawaf CA 29691 
Children’s Memorial Hospital, Chicago, IL Morris Kletzel CA 07431 
Dana-Farber Cancer Institute Holcombe E. Grier CA 41573 
Maine Children’s Craig Hurwitz CA 41573 
Duke University Joanne Kurtzberg CA 15525 
West Virginia University, Morgantown, WV A. Kim Ritchey CA 15525 
University of Maryland Christopher Franz CA 69428 
Yale University Peter Beardsley CA 69428 
Emory University Andrew Yeager CA 20549 
All Children’s Hospital Jerry Levey Barbosa  
Joe DiMaggio Children’s Philippa G. Sprinz  
Tampa Children’s Hospital Cameron K. Tebbi  
Hospital for Sick Children Mark Greenberg  
Medical College Virginia Edward C. Russell  
Miami Children’s Hospital Enrique Escalon  
SUNY Stony Brook Robert Ingalls Parker CA 29293 
University of Vermont Joseph D. Dickerman CA 29293 
Ochsner Clinic Rafael Sanchez Ducos  
Oklahoma University Ruprecht Nitschke CA 11233 
Operations Office Sharon B. Murphy CA 30969 
Cook-Ft. Worth Children’s Medical Center W. Paul Bowman CA 33625 
St. Jude Children’s Ching-Hon Pui CA 31566 
Statistical Office Jonathan J. Shuster CA 29139 
University of Alabama Robert Castleberry CA 25408 
Nemours Children’s Clinic Paul A. Pitel  
University of Florida Paulette Mehta  
University of Kansas Robert C. Trueworthy  
University of Miami Narayana Gowda  
Keesler AFB Hospital Gary D. Crouch CA 15898 
University of Mississippi Medical Center Jeanette Pullen CA 15989 
University of California-Davis Jonathan M. Ducore  
Children’s Hospital (San Diego) Richard P. Kadota CA 28439 
University of Texas-San Antonio Paul Jan Thomas  
Naval Medical Center, Portsmouth Paulette Charese Bryant  
Tripler Army Medical Center Bruce A. Cook  
Walter Reed Army Medical David A. Maybee  
Washington University Michael Rugledge Debaun CA 05587 
Presbyterian Hospital Barry L. Golembe CA 69177 
Wake Forest University School of Medicine Allen Chauvenet  
InstitutionPrincipal investigatorGrant no.
Baylor C. Philip Steuber CA 03161 
Hackensack Medical Center Michael B. Harris  
Boston Floating Hospital Cynthia Sweetnam Kretschmar  
East Carolina University Charles W. Daeschner CA 69177 
Medical University of South Carolina Joseph Laver CA 69177 
Children’s Hospital Michigan Yaddanapudi Ravindranath CA 29691 
St. Johns Hospital Hadi Sawaf CA 29691 
Children’s Memorial Hospital, Chicago, IL Morris Kletzel CA 07431 
Dana-Farber Cancer Institute Holcombe E. Grier CA 41573 
Maine Children’s Craig Hurwitz CA 41573 
Duke University Joanne Kurtzberg CA 15525 
West Virginia University, Morgantown, WV A. Kim Ritchey CA 15525 
University of Maryland Christopher Franz CA 69428 
Yale University Peter Beardsley CA 69428 
Emory University Andrew Yeager CA 20549 
All Children’s Hospital Jerry Levey Barbosa  
Joe DiMaggio Children’s Philippa G. Sprinz  
Tampa Children’s Hospital Cameron K. Tebbi  
Hospital for Sick Children Mark Greenberg  
Medical College Virginia Edward C. Russell  
Miami Children’s Hospital Enrique Escalon  
SUNY Stony Brook Robert Ingalls Parker CA 29293 
University of Vermont Joseph D. Dickerman CA 29293 
Ochsner Clinic Rafael Sanchez Ducos  
Oklahoma University Ruprecht Nitschke CA 11233 
Operations Office Sharon B. Murphy CA 30969 
Cook-Ft. Worth Children’s Medical Center W. Paul Bowman CA 33625 
St. Jude Children’s Ching-Hon Pui CA 31566 
Statistical Office Jonathan J. Shuster CA 29139 
University of Alabama Robert Castleberry CA 25408 
Nemours Children’s Clinic Paul A. Pitel  
University of Florida Paulette Mehta  
University of Kansas Robert C. Trueworthy  
University of Miami Narayana Gowda  
Keesler AFB Hospital Gary D. Crouch CA 15898 
University of Mississippi Medical Center Jeanette Pullen CA 15989 
University of California-Davis Jonathan M. Ducore  
Children’s Hospital (San Diego) Richard P. Kadota CA 28439 
University of Texas-San Antonio Paul Jan Thomas  
Naval Medical Center, Portsmouth Paulette Charese Bryant  
Tripler Army Medical Center Bruce A. Cook  
Walter Reed Army Medical David A. Maybee  
Washington University Michael Rugledge Debaun CA 05587 
Presbyterian Hospital Barry L. Golembe CA 69177 
Wake Forest University School of Medicine Allen Chauvenet  

We thank Joanna Smith for programming help and David Savitz for comments on an earlier draft.

1
Gurney J. G., Davis S., Severson R. K., Fang J. Y., Ross J. A., Robison L. L. Trends in cancer incidence among children in the U.
S. Cancer (Phila.)
,
78
:
532
-541,  
1996
.
2
Gurney J. G., Ross J. A., Wall D. A., Bleyer W. A., Severson R. K., Robison L. L. Infant cancer in the U.
S.: histology-specific incidence and trends
,
1973to1992.J.Pediatr.Hematol.Oncol.,19
:
428
-432,  
1997
.
3
Olshan A. F., Bunin G. R. Epidemiology of neuroblastoma Brodeur G. M. Sawada T. Tsuchida Y. Voute P. A. eds. .
Neuroblastoma.
,
:
33
-39, Elsevier Science B. V. Amsterdam, the Netherlands  
2000
.
4
Everson R. B., Randerath E., Santella R. M., Cefalo R. C., Avitts T. A., Randerath K. Detection of smoking-related covalent DNA adducts in human placenta.
Science (Washington DC)
,
231
:
54
-57,  
1986
.
5
Hansen C., Asmussen I., Autrup H. Detection of carcinogen-DNA adducts in human fetal tissues by 32P-postlabeling procedure.
Environ. Health Perspect.
,
99
:
229
-231,  
1993
.
6
Finette B. A., O’Neill J. P., Vacek P. M., Albertini R. J. Gene mutations with characteristic deletions in cord blood T lymphocytes associated with passive maternal exposure to tobacco smoke.
Nat. Med.
,
4
:
1144
-1151,  
1998
.
7
Ivankovic S. Teratogenic and carcinogenic effects of some chemicals during prenatal life in rats, Syrian golden hamsters, and minipigs.
J. Natl. Cancer Inst.
,
51
:
103
-115,  
1979
.
8
Rice J. M., Ward J. M. Age dependence of susceptibility to carcinogenesis in the nervous system.
Ann. NY Acad. Science
,
381
:
274
-289,  
1982
.
9
Olshan A. F., Faustman E. M. Male-mediated developmental toxicity.
Annu. Rev. Public Health
,
14
:
159
-181,  
1993
.
10
Oke G., Ristow H. Mutagenic, carcinogenic, and teratogenic effects of alcohol.
Mutat. Res.
,
65
:
229
-259,  
1979
.
11
IARC. Acetaldehyde. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Allyl Components, Aldehydes, Epoxides and Peroxides, Vol. 36, pp. 101–132. Lyon, France: IARC, 1985.
12
Dellarco V. L. A mutagenicity assessment of acetaldehyde.
Mutat. Res.
,
195
:
1
-20,  
1988
.
13
Kinney H., Faix R., Braxy J. The fetal alcohol syndrome and neuroblastoma.
Pediatrics
,
66
:
130
-132,  
1980
.
14
Kramer S., Ward E., Meadows A. T., Malone K. E. Medical and drug risk factors associated with neuroblastoma: a case-control study.
J. Natl. Cancer Inst.
,
78
:
797
-804,  
1987
.
15
Schwartzbaum J. A. Influence of the mother’s prenatal drug consumption on risk of neuroblastoma in the child.
Am. J. Epidemiol.
,
135
:
1358
-1367,  
1992
.
16
Robison L. L., Daigle A. Control selection using random digit dialing for cases of childhood cancer.
Am. J. Epidemiol.
,
120
:
154
-156,  
1984
.
17
Brodeur G. M., Maris J. M., Yamashiro D. J., Hogarty M. D., White P. S. Biology and genetics of human neuroblastomas.
J. Pediatr. Hematol. Oncol.
,
19
:
93
-101,  
1997
.
18
Brodeur G. M., Castleberry R. P. Neuroblastoma Pizzo P. A. Poplack D. G. eds. .
Principles and Practice of Pediatric Oncology
,
:
739
-768, Philadelphia, PA. JB Lippincott Company  
1993
.
19
Shapiro D. N., Valentine M. B., Rowe S. T., Sinclair A. E., Sublett J. E., Roberts W. M., Look A. T. Detection of N-myc gene amplification by fluoresence in situ hybridization: diagnostic utility for neuroblastoma.
Am. J. Pathol.
,
142
:
1339
-1346,  
1993
.
20
English P. B., Eskenazi B., Christianson R. E. Black-white differences in serum cotinine levels among pregnant women and subsequent effects on infant birthweight.
Am. J. Public Health
,
84
:
1439
-1443,  
1994
.
21
Klebanoff M. A., Levine R. J., Clemens J. D., DerSimonian R., Wilkins D. G. Serum cotinine concentration and self-reported smoking during pregnancy.
Am. J. Epidemiol.
,
148
:
259
-262,  
1998
.
22
Giovannucci E., Colditz G., Stampfer M. J., Rimm E. B. , Litin, L, Sampson, L, and Willett, W.
C. The assessment of alcohol consumption by a simple self-administered questionnaire. Am. J. Epidemiol.
,
133
:
810
-817,  
1991
.
23
Verkerk P. H., Buitendijk S. E., Verloove-Vanhorick S. P. Differential misclassification of alcohol and cigarette consumption by pregnancy outcome.
Int. J. Epidemiol.
,
23
:
1218
-1225,  
1994
.